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Abstract
The DEAD box RNA helicase p68 (Ddx5) is an important androgen receptor (AR) transcriptional co-activator in prostate
cancer (PCa) and is over-expressed in late stage disease. b-Catenin is a multifunctional protein with important structural and
signalling functions which is up-regulated in PCa and similar to p68, interacts with the AR to co-activate expression of AR
target genes. Importantly, p68 forms complexes with nuclear b-Catenin and promotes gene transcription in colon cancer
indicating a functional interplay between these two proteins in cancer progression. In this study, we explore the relationship
of p68 and b-Catenin in PCa to assess their potential co-operation in AR-dependent gene expression, which may be of
importance in the development of castrate resistant prostate cancer (CRPCa). We use immunoprecipitation to demonstrate
a novel interaction between p68 and b-Catenin in the nucleus of PCa cells, which is androgen dependent in LNCaP cells but
androgen independent in a hormone refractory derivative of the same cell line (representative of the CRPCa disease type).
Enhanced AR activity is seen in androgen-dependent luciferase reporter assays upon transient co-transfection of p68 and b-
Catenin as an additive effect, and p68-depleted Chromatin-Immunoprecipitation (ChIP) showed a decrease in the
recruitment of the AR and b-Catenin to androgen responsive promoter regions. In addition, we found p68
immunoprecipitated with the processive and non-processive form of RNA polymerase II (RNAP II) and show p68 recruited
to elongating regions of the AR mediated PSA gene, suggesting a role for p68 in facilitating RNAP II transcription of AR
mediated genes. These results suggest p68 is important in facilitating b-Catenin and AR transcriptional activity in PCa cells.
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Introduction
The onset and progression of prostate cancer (PCa) is driven by
the transcriptional function of the androgen receptor (AR), and
ablation of androgens is an effective strategy at early stages of the
disease [1]. However, PCa can progress to a castrate resistant
prostate cancer (CRPCa) phenotype that is currently untreatable
[1,2]. Aberrant activation of the AR is thought to play a
prominent role in the development of CRPCa; a process
postulated to be, in part, mediated via uncontrolled activation of
co-activator proteins that facilitate the expression of AR responsive
genes in a minimal hormone environment [3]. Understanding the
molecular events by which progression to CRPCa occurs, may
lead to the identification of novel targets and improve the survival
of patients with disease.
b-Catenin is an integral component of the Wnt pathway,
playing a role in signal transduction. The cytoplasmic stabilisation
and nuclear accumulation of b-Catenin is the ‘hallmark’ of the
activation of the Wnt signalling pathway (see reviews [4,5]). In
prostate cells, b-Catenin is found to be associated with liganded
AR and act as an AR co-activator enhancing both Wnt and
androgen responsive gene transcription (reviewed in [6–8]).
Activated AR is able to shuttle b-Catenin into the nucleus and
enhance AR transcription, indicating a ligand dependent interac-
tion [9]. However, xenografts harvested from castrate resistant
mice also demonstrated increased co-localisation and interaction
of AR and b-Catenin [10]. In LNCaP PCa cells in the absence of
androgens, H2-relaxin mediated phosphorylation of Akt and
GSK-3b caused the stabilised cytoplasmic accumulation of b-
Catenin which subsequently bound to the AR and translocated
into the nucleus, suggesting that the presence of androgens is not
essential for the interaction between AR and b-Catenin under
certain conditions [11]. Interestingly, co-localization and interac-
tion of AR and b-Catenin was not seen in tumours harvested from
non-castrated mice, suggesting that this interaction is specific to
the progression of PCa to CRPCa and warrants further
investigation. Direct evidence of b-Catenin as part of the AR
transcriptional complex has been demonstrated through Chroma-
tin Immunoprecipitation (ChIP) studies, which show b-Catenin
recruited to the promoter regions of both androgen and Wnt
responsive genes in the presence and absence of androgens
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[11,12]. Further evidence suggests that the growth of metastatic
prostate tumour cells in the bone is via androgen mediated Wnt
activation [13], and increased nuclear b-Catenin levels have been
correlated with prostate cancer disease progression [14,15]. In
addition, reduction or loss of E-cadherin which normally
sequesters b-Catenin at the plasma membrane is postulated to
increase levels of cellular b-Catenin and promote AR activity [7].
Collectively, the data suggest an important role for b-Catenin in
the progression of PCa to the CRPCa phenotype. However, it is
clear that the precise mechanisms by which b-Catenin mediates
AR transcriptional activity and growth of CRPCa in the absence
of androgens, deserves further investigation.
The RNA helicase p68 (Ddx5) is a growth- and developmen-
tally- regulated prototypic member of the DEAD box family of
helicases. p68 functions in many cellular processes commonly
dysregulated in cancer including processing of pre-mRNA and
alternative splicing, cell proliferation, microRNA processing
(reviewed in [16,17]), and ribosome biogenesis [18]. p68 is also
known to interact with several components of the transcriptional
complex and to co-activate various transcription factors such as
tumour suppressor p53, Estrogen Receptor a (ERa) and b-
Catenin (reviewed in [16,19,20]). We have previously demon-
strated p68 over-expressed in PCa and functioning as a co-
activator of the AR [21]. In addition to prostate tumours, p68 is
over-expressed in many other cancer cell types such as colon and
breast, suggesting that p68 acts as a potential tumour promoter (
[22] and reviewed in [17]). p68 and the highly homologous protein
p72 (Ddx17), are over-expressed and form complexes with b-
Catenin in the nucleus of colon cancer cells to activate gene
transcription and promote cell proliferation [22–24]. Tyrosine
593-phosphorylated p68 also associated with b-Catenin in the
cytoplasm of colon cancer cells, where it promoted b-Catenin
nuclear translocation via a RanGTPase Wnt-independent path-
way through interaction with b-Catenin and displacement of Axin
[25,26]. However, conflicting research found no evidence that p68
was required for nuclear translocation of b-Catenin in the same
cell type [27], and tyrosine 593-phosphorylated p68 did not differ
from wild-type in its ability to stimulate b-Catenin dependent
transcription in another study [23].
In this article, we use immunoprecipitation, ChIP and luciferase
reporter techniques in combination with siRNA oligo nucleotide
knockdown, to explore the relationship of p68 with b-Catenin to
understand the molecular mechanism by which they potentially
mediate aberrant activation of the AR and growth of PCa cells, as
part of the AR transcriptional complex.
Results
p68 and b-Catenin Interact in the Nucleus of PCa Cells
Given that the androgen receptor (AR) associates independently
with b-Catenin and p68 in PCa cells [21,28], and p68 and b-
Catenin interact in colon cancer cells [23]. We speculate a possible
three-way protein interaction between the AR, b-Catenin and p68
in PCa cells. Ligand free AR is sequestered within the cytoplasm of
PCa cells and upon hormone binding moves predominantly into
the nucleus [29]. Previously, we found p68 to be a nuclear protein
in PCa cells whose localisation was unaltered by androgen
treatment [21]. However, p68 has been found in the cytoplasm
of colon cancer cells where it associates with b-Catenin [23,25],
and b-Catenin has been shown to interact with the AR in the
cytoplasm of PCa cells and move into the nucleus in the presence
and absence of androgens [9–11]. In light of these findings, we
sought to confirm the localisation of b-Catenin and p68 in the
LNCaP and the hormone refractory LNCaP-AI PCa cell line (see
materials and methods). As expected in response to R1881
treatment (10 nM), AR translocated into the nucleus in both
LNCaP and LNCaP-AI cells (Figure 1A). Androgen treatment did
not significantly alter the nuclear localisation of p68 in either
LNCaP or LNCaP-AI cells and similarly, the localisation of b-
Catenin was unchanged upon R1881 treatment. Proportionally
less b-Catenin is found in the nucleus compared to the cytoplasm
of LNCaP cells, with proportionally higher in the LNCaP-AI cell
type. This reflects previous findings that demonstrated AR
constitutively shuttles b-Catenin into the nucleus of LNCaP-AI
cells as an adaptation to androgen independent conditions [10,12].
Co-immunoprecipitation of HCT-116 cell lysates with b-
Catenin antibody identified an endogenous p68 interaction with
b-Catenin in whole lysates of colon cancer cells [23]. Further
analysis using Myc-tagged truncations of p68 demonstrated that
the COOH terminus of p68 was unable to interact with b-
Catenin, and the interaction was through the helicase (N-terminal)
domain of p68. Following our immuno-blot findings in Figure 1A
where both b-Catenin and p68 were found in the nucleus of
LNCaP and LNCaP-AI cells in the presence and absence of
androgens, we investigated whether p68 and b-Catenin directly
interacted in the nucleus of PCa cells. Figure 1B shows ectopic co-
immunoprecipitation of over-expressed myc-tagged p68 and b-
Catenin fusion proteins in the androgen receptor negative COS-7
cell line, in both the presence and absence of R1881 (10 nM).
Demonstrating that under in-vitro conditions, p68 and b-Catenin
are able to directly bind independently of AR and androgens.
(N.B. the higher band in the b-Catenin immunoprecipitation blot
is a non-specific band detected by the myc antibody). However,
endogenous protein immunoprecipitated from nuclear LNCaP
extracts showed the b-Catenin-p68 interaction was facilitated in
the presence of androgens (R1881, 10 nM), but conversely in the
LNCaP-AI cell line the interaction was facilitated in the absence of
androgens (R1881, 10 nM) (Figure 1C). (N.B. the reverse
immunoprecipitation using b-Catenin antibody to pull down p68
protein failed to show an interaction between the two proteins in
either the LNCaP or LNCaP-AI cell type, despite numerous
attempts with various antibodies to b-Catenin). We also found no
endogenous interaction between p68 and b-Catenin in the AR
negative PC3 cell line (see Figure S1 in supporting information),
indicating that the presence of a functional AR is possibly
important for an endogenous interaction of p68 and b-Catenin in
PCa cells [21,28].
p68 Interacts with RNAP II and is Recruited to Functional
Regions of the PSA Gene
We have previously described p68 as functioning as an ‘adaptor’
or ‘coupling’ protein that may coordinate the tightly integrated
processes of transcriptional initiation, elongation and mRNA
splicing in AR-regulated gene expression [30]. Recruitment of p68
to endogenous AR responsive genes may facilitate spliceosome
assembly and increase the rate of RNA polymerase II (RNAP II)
elongation, affecting splice site recognition and promoting exon
skipping in nascent transcripts. Due to the established roles b-
Catenin and p68 play in the transcriptional initiation of AR
regulated genes, we sought to expand on these findings and
investigate the relationship of p68 with RNAP II in PCa cells. We
found p68 immunoprecipitated with both endogenous processive
(phosphorylation at ser-2) and non-processive (phosphorylation at
ser-5) forms of RNAP II in PCa cells, in both the presence and
absence of androgens (Figure 2A R1881, 10 nM treatment).
Indicating a possible role for p68 activity (in addition to AR co-
activator function), during the elongation stages of AR regulated
transcription. We previously demonstrated by Chromatin-Immu-
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noprecipitation (ChIP) and QPCR analysis over a 100 minute
androgen treatment (R1881, 10 nM) time course, a co-recruitment
of p68 with the AR at the androgen responsive promoter and
enhancer regions of the AR regulated PSA gene [21]. Expanding
on these findings, we optimised QPCR primers to other areas of
the PSA gene (in-between the enhancer and promoter region (E-P),
exon 1, intron 2, exon 3, intron 3, exon 5 and 39dsF regions), to
establish whether p68 was recruited to sites other than transcrip-
tional initiation. (N.B. The primer location and sequence
information for these regions can be found in Table S1 in
supporting information. It was not possible to optimise QPCR
primers to intron 1, exon 2, intron 4 or exon 4 regions of the PSA
gene). Figure 2B shows significant (p,0.05*) differential enrich-
ment of AR upon R1881 treatment (10 nM) at set time points (0,
15, 30, 45, 90 and 120 minutes) to the ARE III region of the PSA
gene, as demonstrated previously [31]. Enrichment of AR at other
regions was not seen. Similarly, figure 2C shows significant
(p,0.005**) cyclical dissociation-association recruitment of p68
upon R1881 treatment (10 nM) to the ARE III region, although
recruitment was not limited to this region as E-P, Exon 3, Intron 3,
Exon 5 and 39dsF regions also showed significant enrichment.
Recruitment did not reach significance at ARE I, Exon 1 and
Intron 2 regions. These findings imply p68 is associated with both
transcriptional initiation and elongation forms of RNAP II and
enriched not only at the transcriptional start sites of a AR
regulated gene but at exonic, intronic and 39dsF regions,
indicating a possible function for p68 in facilitating the processing
of AR gene transcription by RNAP II.
Figure 1. Localisation and interaction of p68 and b-Catenin in PCa cells. A. Cropped immuno-blot images show cytoplasmic and nuclear
LNCaP and LNCaP-AI PCa cell lysates (+/2 R1881 10 nM, 8 hours), probed sequentially with b-Catenin, AR, p68, a-tubulin and TATA binding (TBP)
antibodies. B. Interaction of ectopic p68 and b-Catenin in COS-7 cells. Whole cell lysates of COS-7 cells transfected with pcDNA3-p68-myc and pCS
3+-
Myc6-b-Catenin constructs (+/2 R1881 10 nM, 8 hours), were immunoprecipitated with b-Catenin and p68 antibody respectively. Cropped immuno-
blots were probed sequentially with b-Catenin, p68 and myc antibody.C. Interaction of endogenous p68 and b-Catenin in the nucleus of LNCaP and
LNCaP-AI PCa cells in the presence and absence of androgens. Cropped immuno-blot images of LNCaP and LNCaP-AI nuclear lysates,
immunoprecipitated with p68 antibody (+/2 R1881 10 nM, 8 hours), and probed sequentially with b-Catenin and p68. Extract samples contain either
whole cell or nuclear lysate and protein G sepharose with no antibody present. Control (Con) samples contain antibody and protein G sepharose in
extraction buffer only.
doi:10.1371/journal.pone.0054150.g001
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p68 Function is Required for Recruitment of AR and b-
Catenin to the Promoter Regions of Androgen
Responsive Genes
We have previously shown a decrease in mRNA and protein
levels of the AR and the androgen responsive PSA gene upon p68
knockdown by siRNA [21]. Consistent with the ChIP findings
described above, b-Catenin is recruited to the promoter and
enhancer regions of androgen responsive and Wnt signalling target
genes in both the presence and absence of androgens [11,12]. In
light of these findings, we performed ChIP experiments in LNCaP
cells depleted of p68 by siRNA to establish whether p68 function
was required for AR and b-Catenin recruitment to the promoter
regions of androgen responsive genes. p68 targeted siRNA
knockdown expression (attenuation of p68 mRNA ,50%
p,0.0494* and protein,90% at 72 hrs post transfection), did
not significantly alter b-Catenin mRNA or protein expression
levels compared to control (non-silencing, NS) siRNA in LNCaPs
cells, in the presence or absence of R1881 (Figure 3A, B and C
respectively). Androgen stimulation facilitated a modest (0.8 fold)
recruitment of AR to the ARE I region of the PSA promoter in
control (NS) siRNA transfected LNCaP cells as expected
(Figure 4A), which was significantly attenuated to control levels
in p68 depleted cells (p,0.0077**). Similarly, androgen stimula-
tion increased AR recruitment to the ARE III enhancer region of
the PSA gene 9 fold in control (NS) siRNA transfected cells
(Figure 4B), whilst in p68 depleted cells, recruitment to the same
region was reduced by 4 fold (p,0.0008***). A similar pattern of
attenuation in AR recruitment was also seen at KLK2 (0.25 fold,
p=0.1593 Figure 4C) and TMPRSS2 (1 fold, p,0.0016**
Figure 2. p68 interacts with RNAPII in PCa cells and occupies many regions of the PSA gene. A. Cropped immuno-blot images of LNCaP
nuclear lysates immunoprecipitated with RNAP II H5 (ser-2), RNAP II H14 (ser-5), RNAP II CTD mouse monoclonal and p68 antibody (+/2 R1881
10 nM, 8 hours), probed sequentially with p68 and RNAP II antibody. Extract samples contain nuclear cell lysate and protein G sepharose with no
antibody present. Control samples contain antibody and protein G sepharose in nuclear extraction buffer only. B. Recruitment of AR and C. p68 to
regions of the PSA gene. LNCaP cells were treated with 10 nM R1881 and harvested at 0, 15, 30, 45, 90 & 120 minute time points. Samples were
immunoprecipitated with AR, p68 or control IgG antibodies and recovered material processed by ChIP assay. QPCR data are representative of n = 3
independent ChIP assays normalised to input levels (+/2 SE). (N.B. QPCR primers could not be optimised to all exonic and intronic regions of the PSA
gene). The independent paired sample t test was used to compare enrichment in recruitment between different PSA regions and show significance.
D. Diagram of PSA gene depicting exon/intron boundaries.
doi:10.1371/journal.pone.0054150.g002
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Figure 4D) promoter regions in p68 targeted siRNA depleted cells
upon R1881 treatment, although this did not reach significance
and androgen stimulation did not show enrichment of AR
recruitment at the KLK2 promoter. However, we have seen
recruitment of the AR to the KLK2 promoter at other time points
(data not shown). Interestingly, a similar pattern in attenuation of
b-Catenin recruitment upon p68 targeted siRNA knockdown was
also seen. Increased b-Catenin recruitment to both ARE I (0.6
fold) and ARE III (0.8 fold) regions was observed upon androgen
stimulation in control (NS) siRNA transfected cells compared to
non-treated cells (Figure 4E and 4F respectively), as expected.
However, in p68 depleted cells, b-Catenin recruitment was
significantly attenuated to below control (NS) siRNA levels at
both regions (1.1 fold, p,0.0023** and 1.3 fold, p,0.0011**
respectively). A similar pattern of b-Catenin de-recruitment was
repeated at the KLK2 and TMPRSS2 promoter in p68 depleted
cells (1.25 fold, p,0.0003*** Figure 4G, and 1 fold, p,0.0005***
Figure 4H respectively). Although it is of note that in contrast to
AR recruitment, an increase in b-Catenin recruitment (1.75 fold) is
seen at the KLK2 promoter region at this androgen time point. We
have reported a decrease in AR mRNA and protein levels upon
p68 depletion in LNCaP cells previously [21], supporting the
notion that p68 functions as an AR co-activator. Therefore, a
reduction in the recruitment of AR to the promoter regions of
androgen responsive genes in p68 depleted cells would be expected
as the AR itself is an androgen responsive gene. However in p68
depleted cells, we found b-Catenin recruitment reduced to levels
lower than non-treated cells at all promoter regions assessed
(similar to IgG levels). Suggesting direct p68 interaction may be
required to facilitate the loading of b-Catenin to transcriptionally
active regions of androgen responsive genes. This data highlights
the importance of p68 function in the recruitment of the co-
activator b-Catenin and the AR to the promoter regions of
androgen responsive genes.
p68 and b-Catenin Additively Enhance the
Transcriptional Activity of Androgen Receptor Regulated
Genes
Given that p68 and b-Catenin interact in PCa cells and p68
facilitates the recruitment of b-Catenin to androgen responsive
gene promoters. We next chose to investigate the combined effect
of co-expression of p68 and b-Catenin on the transcriptional
activity of the AR using androgen-dependent luciferase reporter
assays in COS-7 cells. The AR-mediated p(ARE)3 Luc reporter
was robustly stimulated 2 fold by the AR upon R1881 (10 nM)
androgen treatment (Figure 5, compare light grey bar +R1881 and
dark grey bar –R1881). Over-expression of b-Catenin showed
negligible p(ARE)3 Luc reporter activity in the presence or absence
of R1881 demonstrating that b-Catenin does not directly affect
p(ARE)3 Luc reporter activity in the absence of AR. However, co-
expression of AR and b-Catenin showed an 8 fold increase in
p(ARE)3 Luc reporter activity upon R1881 treatment, confirming
b-Catenin as a co-activator of the AR consistent with previous
findings [28]. Similarly, co-expression of AR and p68 showed a 5
fold increase in p(ARE)3 Luc reporter activity following R1881
treatment, also confirming p68 as a co-activator of the AR
consistent with previous findings. (N.B. p68 has been shown to not
affect p(ARE)3 Luc reporter activity directly in the absence of AR
[21]). However, co-expression of AR, b-Catenin and p68
constructs demonstrated a significant 18 fold (p,0.0011**)
increase in p(ARE)3 Luc reporter activity upon R1881 treatment,
10 fold higher than AR and b-Catenin co-expression, demon-
strating p68 has a significant additive effect on AR and b-Catenin
transcriptional activity. This was also seen with another androgen
regulated PSA promoter luciferase reporter (p(PSA) Luc), whereby
co-expression of AR, b-Catenin and p68 constructs showed a
significant 8 fold (p,0.0057**) increase in reporter activity, 5 fold
higher than AR and b-Catenin co-expression, confirming the
additive effect of p68 on b-Catenin and AR transcriptional activity
(see supporting information, Figure S2). p68 has been reported to
form heterodimers with the highly homologous helicase p72
(DdX17), and co-activate b-Catenin mediated gene expression
previously [23]. We found that co-transfection of AR, b-Catenin
and p72 constructs did not have a significant additive effect on
p(ARE)3 Luc reporter activity compared to co-transfection of AR,
b-Catenin and p68 constructs (see supporting information, Figure
S3 p=0.3646). This is similar to a previous report that found p72
was unable to enhance AR transcriptional activity of the p(ARE)3
Luc reporter [21], and suggests a specificity for p68 in the
transcriptional activation of the AR in PCa. Collectively, these
data suggest b-Catenin and p68 may work together as co-
activators to enhance AR regulated transcription.
Figure 3. Knockdown of p68 does not alter b-Catenin mRNA or protein expression. mRNA expression levels of p68 A. and b-Catenin B. in
control (NS) and p68 siRNA-transfected LNCaP cells (+/2 R1881 10 nM, 16 hours). QPCR data was normalised to GAPDH levels and fold change
calculated relative to control (NS) (-R1881) mRNA levels (set as 1). The independent sample t test was used to compare differences in expression levels
and show significance. C. Cropped immuno-blot images of lysates from LNCaP cells treated with 10 nM R1881 (16 hours) and transfected with
control (NS) and p68 siRNA. Blots probed sequentially with b-Catenin, p68 and a-tubulin antibodies.
doi:10.1371/journal.pone.0054150.g003
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Discussion
In this study, we describe a functional interaction between p68,
b-Catenin and the AR in the nucleus of PCa cells. The AR has
been shown to signal through the Wnt/b-Catenin pathway in PCa
as an adaptation to castrate levels of androgens [12], and b-
Catenin is known to interact with other co-activators of the AR
[32]. Here we present immunoprecipitation, p68-depleted ChIP
and PSA luciferase reporter data to confirm an interaction between
p68, b-Catenin and the AR in PCa cells. We initially confirmed a
direct in-vitro p68-b-Catenin interaction by transient transfection of
constructs into the AR negative COS-7 cell line (which was not
androgen dependent). However, upon further investigation we
found under endogenous conditions the p68-b-Catenin interaction
was facilitated in the presence of androgens in the LNCaP PCa cell
line, but conversely in the hormone refractory (LNCaP-AI)
derivative of this cell line (representative of the CRPCa disease
type), the interaction was facilitated in the absence of androgens.
This is similar to a finding of increased endogenous AR/b-Catenin
complex formation in a castrate resistant PCa mouse xenografts
model, where no interaction between AR and b-Catenin was
detected in the presence of androgens [10]. This may suggest an
adapted mechanism by which p68 and b-Catenin co-activators co-
operatively maintain transcriptional activity of the AR (and
androgen regulated genes), facilitating cell survival of the
castrate-resistant (CRPCa) disease type. However, further work
is required to substantiate the full molecular mechanism of this
claim. Immuno-blot data confirmed the cellular localisation of p68
and b-Catenin was not influenced by hormone (we found p68 and
b-Catenin in the nucleus of PCa cells in both the presence and
absence of androgens), and PSA luciferase reporter data showed
co-transfection of p68 and b-Catenin constructs had an additive
Figure 4. Depletion of p68 reduces AR and b-Catenin recruitment to promoter regions of androgen responsive genes. LNCaP cells
transfected with p68 or control (NS) siRNA, treated with 10 nM R1881 for 90 minutes and immunoprecipitated with either AR A. B. C. & D. or b-
Catenin E. F. G. & H. antibodies (including a IgG control antibody). Recovered material was processed by ChIP assay and recruitment to PSA ARE I (A
& E), ARE III (B & F), KLK2 (C & G) & TMPRSS2 (D & H) promoter regions assessed relative to 0 minute time point. p68 depletion in LNCaP cells showed
reduced AR & b-Catenin recruitment after treatment with 10 nM R1881 for 90 minutes to all regions assessed compared to control (NS) siRNA cells.
Results shown represent n= 3 independent experiments (+/2 SD). The independent sample t test was used to compare differences in expression
levels and show significance.
doi:10.1371/journal.pone.0054150.g004
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effect on the transcriptional activity of AR in the presence of
androgens. These data suggest that p68 and b-Catenin work
together as co-activators to additively enhance the transcriptional
activity of the AR which interestingly, may have implications in
the progression of the CRPCa disease type.
We also showed using knockdown of p68 expression by siRNA
oligonucleotide combined with ChIP, that p68 was required for
optimal recruitment of the AR and b-Catenin to promoter regions
of androgen regulated genes. Androgen stimulation facilitated
recruitment of the AR to both ARE I and ARE III regions of the
PSA promoter, and KLK2 and TMPRSS2 promoter regions in
control (NS) siRNA transfected LNCaP cells, which was subse-
quently attenuated in p68 depleted cells. The observed b-Catenin
recruitment to the same androgen regulated promoter regions was
reduced in p68 depleted LNCaP cells upon androgen treatment,
but to levels lower than non-treated cells (similar to the IgG
control). This is an interesting finding as it suggests that a
reduction in the recruitment of b-Catenin to the promoter regions
of androgen regulated genes in p68 depleted cells is not just a
consequence of less AR available for recruitment, and implies that
p68 function is required to load b-Catenin to transcriptionally
regulated regions of androgen responsive genes.
The role of p68 in alternative mRNA splicing is well
documented (reviewed in [19,21,33]). We have previously
speculated that p68 may function as an ‘adaptor’ or ‘coupling’
protein that coordinates the tightly integrated processes of
transcription and RNA processing, facilitating cross-talk between
transcription and RNA processing in AR-regulated genes,
possibly by controlling the rate of transcriptional initiation/
elongation of RNAP II [30]. RNAP II has two physiologically
important phosphorylation sites at the C-terminus which are
important for transition of the polymerase from a transcriptional
initiation form (phosphorylation at ser-5), to the establishment of
the elongation transcriptional complex form (phosphorylation at
ser-2). In this study, we demonstrate using endogenous nuclear
extracts of LNCaP PCa cells, that p68 interacts with both the
processive (phosphorylation at ser-2) and non-processive (phos-
phorylation at ser-5) form of RNAP II, in the presence and
absence of androgens. These findings directly link p68 to RNAP
II during transcriptional initiation and elongation in PCa cells,
suggesting that p68 (in addition to its role as an established AR
transcriptional co-activator), could potentially facilitate the
elongation of AR regulated genes. This is supported by ChIP
data that provides evidence of p68 not only occupying promoter
and enhancer regions of the AR regulated PSA gene, but also
in-between the enhancer and promoter region and at exonic
and intronic regions. Collectively, this suggests p68 has the
potential to support RNAP II function at elongating regions of
the PSA gene. ChIP recruitment data was gathered at set time
points of androgen stimulation and recruitment to all areas of
the PSA gene was seen in the absence of androgens.
Immunoprecipitation data also showed p68 interacted with
both forms of RNAP II in the absence of androgens. This
suggests that p68 is possibly pre-loaded to transcriptionally
active areas of the PSA gene ready for the start of transcription
in a similar mode by which RNAP II is found ‘poised’ at
transcriptionally active gene regions prior to transcriptional
initiation [34], possibly facilitating potential ‘cross-talk’ between
Figure 5. Over-expression of p68 additively enhances activity of b-Catenin mediated AR transcription. COS-7 cells transiently
transfected in triplicate with p(ARE)3Luc reporter and PCMV-b-galactosidase plasmids together with mammalian expression vectors for AR, b-Catenin
and p68 (+/210 nM R1881). Luciferase activity was corrected for the corresponding b-galactosidase activity to give relative activity. The range of
plasmid levels (+ and ++) corresponds to 50 and 100 ng respectively. Data shown relative to AR activity alone (2R1881) (set as 1), and representative
of at least n = 3 luciferase assay experiments (+/2 SE). The independent sample t test was used to compare differences in expression levels and show
significance.
doi:10.1371/journal.pone.0054150.g005
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the AR and RNAP II. The notion that p68 is functioning as an
adaptor, co-ordinating transcription and mRNA processing of
AR regulated genes, is also consistent with the established role
of p68 as a functional splicing factor [21,35]. We also found
association-dissociation recruitment of p68 at the 39dsF region
of the PSA gene suggesting a role for p68 in the termination
and polyadenylation of AR mediated transcripts, consistent with
a previous report that described p68 involved in transcriptional
deactivation in Drosophila promoting mRNA transcript release
[36]. During the preparation of this manuscript, Germann et al.
published a manuscript which demonstrated p68 (Ddx5) and the
highly homologous p72 (Ddx17) protein have a dual role in the
control of transcription of the pro-migratory NFAT5 transcrip-
tion factor (in addition to their role in facilitating the inclusion
of NFAT5 exon 5), in breast cancer cells [37]. This work
strengthens our findings and suggests p68 is possibly working as
a ‘coupling’ factor to facilitate not only AR-regulated transcrip-
tion in PCa, but other nuclear transcriptional factors in
alternative cancer types. However, further work will be required
to expand on these findings.
Collectively, the data presented in this manuscript has
corroborated previous findings which identified p68 as an
important co-activator of the AR, and expanded on these
foundations to identify a novel role for p68 in facilitating the
recruitment of not only the AR but the AR co-activator b-Catenin
to androgen regulated genes. We demonstrate that p68 is not only
integral to AR regulated transcription at the promoter level
(transcriptional initiation), but also during elongation and tran-
scriptional progression and may have the potential to influence the
expression of AR regulated genes through direct interaction with
RNAP II. Taken together, these data provide evidence that p68 is
required for transcriptional regulation of AR mediated genes and
is of importance in the recruitment of AR co-factors to the AR
transcriptional complex. This may be of significance in the
progression of the CRPCa disease type.
Materials and Methods
Cell Culture
All cells were grown at 37uC in 5% CO2. LNCaP and PC3 cells
(American Type Culture Collection, ATCC, Manassas, VA), were
cultured in RPMI-1640 and COS-7 cells (ATCC) in D-MEM
media, both supplemented with 1% L-glutamine (Invitrogen) and
10% foetal calf serum (FCS) (Invitrogen). LNCaP-AI cells derived
from the LNCaP cell line following continuous passaging in steroid
depleted media for 8 months to gain androgen independence have
been described previously [38], and were cultured in RPMI-1640
supplemented with 1% L-glutamine (Invitrogen) and 10%
Dextran Charcoal Stripped FCS (Hyclone), to produce steroid-
depleted media (SDM). Where indicated in figure legends, cells
were treated with 10 nM of the synthetic androgen R1881
(Methyltrienolone).
Plasmids, Antibodies and Drugs
The following plasmids have been described previously,
p(ARE)3 Luc, PSA promoter Luc, pCMV-b-galactosidase,
pcDNA3-AR, pcDNA3-p68, pcDNA3-p72 [21,39]. The pCS
3+-
Myc6-b-Catenin and pSG5-AR constructs were kind gifts from
Professor Ralf Janknecht (Mayo Clinic College of Medicine, USA)
[23]. The following antibodies were used as indicated in figure
legends; goat polyclonal p68 C-20 and mouse monoclonal b-
Catenin 8E4 (Santa Cruz), mouse monoclonal p68 PAb204 and
RNA polymerase II CTD4H8 (Millipore), mouse monoclonal AR
(BD Pharmingen), rabbit polyclonal b-Catenin and mouse
monoclonal TATA Binding Protein TBP (Abcam), mouse
monoclonal RNA polymerase II CTD 8WG16, H5 (Ser2) and
H14 (Ser5) (Covance), mouse monoclonal a-tubulin (Sigma) and
mouse monoclonal Myc-Tag 9B11 (Cell Signalling). The p68 2906
rabbit polyclonal (raised against the C-terminal 15 residues of p68)
has been described previously [40,41].
Luciferase Reporter Assays
Luciferase reporter assays were performed in COS-7 cells co-
transfected in triplicate with 0.1 mg of p(ARE)3Luc or p(PSA)Luc,
pcDNA3-AR or pSG5-AR and pCMV-b-galactosidase using
Superfect (Qiagen), as described previously [31]. pcDNA3-p68,
pcDNA3-p72 and pCS
3+-Myc6-b-Catenin fusion constructs were
co-transfected into cells as detailed in figure legends. The range of
plasmid levels indicated in figures (+ and ++) corresponds to 50
and 100 ng respectively. Luciferase activity was corrected for
corresponding b-galactosidase activity to give relative activity. All
reporter assays are the mean of at least three independent
experiments 6 standard error.
Cell Lysate Preparation and Co-Immunoprecipitation (IP)
LNCaP or LNCaP-AI cells were cultured in SDM for 48 hours
prior to 10 nM R1881 treatment, (8 hours). Cells were nuclear
extracted using CelLyticTM NuCLEARTM Extraction kit (Sigma,
UK) with an extraction buffer salt concentration of 330 mM in the
presence of protease inhibitors (Roche, UK), and RNase A
(100 mg/ml - Sigma). All immunoprecipitation experiments were
performed as described previously [42].
siRNA Knockdown and Quantitative Real-Time PCR (RT-
QPCR)
LNCaP cells seeded in 6-well plates were reverse transfected
with p68 or control (non silencing, NS) small interfering RNA
(siRNA) (see [43,44] for sequences), using lipofectamine RNAiMax
(Invitrogen, according to the manufacturer’s instructions), and
grown in SDM for 48 hours prior to treatment with 10 nM R1881
for a further 16 hours. Cells were harvested in either SDS-sample
buffer to acquire protein for western blot analysis or TRIzol
reagent (Invitrogen) followed by MMLV reverse transcription to
study mRNA expression by RT-QPCR relative to GAPDH, as
previously described [44]. b-Catenin (Forward AGGC-
TACTGTTGGATTGATTCGAA and Reverse CAT-
GATTTGCGGGACAAAGG), p68 and GAPDH oligonucleo-
tides (described previously [21]), were used to determine mRNA
expression.
Chromatin-Immunoprecipitation (ChIP) Assays
LNCaP cells seeded in 90mM dishes were reverse transfected
with p68 or NS siRNA as described above and cultured in SDM
for 48hours prior to 10 nM R1881 treatment for 90 minutes. ChIP
was undertaken on siRNA treated cells using both AR and b-
Catenin antibodies and an IgG antibody was included as a control,
as described previously [21]. QPCR was subsequently performed
on inputs and recovered material to assess the occupancy of AR
and b-Catenin at the promoter ARE I and enhancer ARE III
regions of the PSA gene, and the androgen responsive promoter
regions of the KLK2 and TMPRSS2 genes (see Table S1 in
supporting information for primer sequences). To assess p68 and
AR occupancy at the promoter, coding and 3-UTR regions of the
PSA gene, LNCaP cells were cultured in SDM for 48 hours prior
to 10 nM R1881 treatment (at set time points as stipulated in the
figure legend). The following regions were assessed for p68, AR
and IgG (control antibody) occupancy: AREIII, AREI, in between
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the enhancer and promoter regions (E-P), Exon I, Intron 2, Exon
3, Intron 3, Exon 5 and the 39dsF. The primer sequences for ARE
III, ARE I and E-P have been described previously [42,45]. All
other QPCR primer sequences were optimised for this study and
can be found in supporting information (Table S1), including
primer position on the PSA gene. ChIP sonication products were
optimised to robustly yield fragments of less than 500 bp to allow
discrimination between all regions examined. ChIP results are
representative of at least three independent experiments 6
standard error. IgG control ChIP was performed on the longest
androgen treatment set time point (120 min).
Statistical Analysis
The independent sample t test was used with GraphPad Prism 6
software (GraphPad Software, Inc), to compare differences as
stipulated in figure.
Supporting Information
Figure S1 Immunoprecipitation of endogenous p68 and
b-Catenin in an AR negative PC3 cell line do not interact.
Cropped immuno-blot images of PC3 whole cell lysates,
immunoprecipitated (IP) with either p68 or b-Catenin antibody
and probed sequentially with b-Catenin and p68. Extract samples
contain whole cell lysate and protein G sepharose with no
antibody present, and Control (Con) samples contain antibody and
protein G sepharose in extraction buffer only.
(TIF)
Figure S2 Over-expression of p68 additively enhances
the activity of b-Catenin mediated AR transcription by
an AR mediated PSA promoter luciferase reporter. COS-
7 cells were transiently transfected in triplicate with 0.1 mg of
p(PSA)Luc reporter, 0.1 mg pSG5-AR, 0.1 mg of pCMV-b-
galactosidase and 0.05 mg of pcDNA3-p68 or pCS3+-Myc6-b-
Catenin constructs (+10 nM R1881). Luciferase activity was
corrected for the corresponding b-galactosidase activity to give
relative activity. The range of plasmid levels (+ and ++)
corresponds to 50 and 100ng respectively. Data is shown relative
to AR activity alone (set as 1) and from at least three independent
luciferase assay experiments (+/2 SE).
(TIF)
Figure S3 Over-expression of p72 does not enhance the
activity of b-Catenin mediated AR transcription. COS-7
cells were transiently transfected in triplicate with 0.1 mg of
p(ARE)3 luciferase reporter, 0.1 mg pcDNA3-AR, 0.1 mg of
pCMV-b-galactosidase and 0.05 mg of pcDNA3-p72, p68 or
pCS3+-Myc6-b-Catenin constructs (+10 nM R1881). Luciferase
activity was corrected for the corresponding b-galactosidase
activity to give a relative activity. The range of plasmid levels (+
and ++) corresponds to 50 and 100 ng respectively. Data is shown
relative to AR and b-Catenin activity alone (set as 1) and from at
least three independent luciferase assay experiments (+/2 SE).
(TIF)
Table S1 Sequences for primers used in ChIP experi-
ments and location of primers on the PSA gene.
(TIF)
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